

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

14 October 2020

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(11 pages by email)


Dear Madam

### **PRESENTATION TO INVESTORS**

I attach a PowerPoint presentation, which is being presented by Biotron Limited's Managing Director, Dr Michelle Miller, to investors.

This announcement has been approved by the Company's Managing Director.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn10527

### **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333

**BIOTRON LIMITED**  
**(ASX:BIT)**

**Investor Update**  
October 2020



# Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

# Biotron Overview

- Clinical stage company developing small molecule drugs targeting big health problems:
  - HIV-1, Hepatitis B, COVID-19, Dengue and others
- **Positive data in trials to date including a successful HIV-1 Phase 2 trial**
  - Potential for improved health outcomes and eradication of reservoirs of HIV-1
  - Provides clinical validation of Biotron's approach to treating serious virus infections
- Biotron has had a long-standing interest in Coronaviruses (CoVs) since SARS-1 outbreak
  - **Reinstated and expanded this program to cover SARS-CoV-2 in response to the COVID-19 pandemic**
- Experienced Board and management team with big pharma, financial and VC backgrounds
- Headquartered in Sydney, Australia
- Robust pipeline of drugs targeting serious virus infections
  - Partnering opportunities across multiple indications



# Key Achievements in Last 12 Months

- Raised \$5.8 million in Dec 2019 from exercise of BITOB options
- Reported positive results from the Phase 2 HIV-1 clinical trial of BIT225
  - Set up world-class Advisory Board of international HIV-1 experts
  - Appointed US-based Chief Medical Officer
  - Presented key data on BIT225 at international meetings
  - Filed new patent applications based on Phase 2 data
  - Completed 6-month toxicology studies of BIT225 to support long-term dosing in human trials
- Expanded antiviral screening program to include SARS-CoV-2, the causative agent of COVID-19
  - Identified a series of Biotron compounds with *in vitro* activity against SARS-CoV-2
- Good progress with promising Hepatitis B Virus (HBV) program
- Focus on commercialisation activities and setting up technology for Phase 3 and beyond



# SARS-CoV-2

- Biotron's core expertise is designing drugs to target a key viral protein found on a range of different viruses
  - Biotron researchers were first to identify and report on this protein (E protein) on coronaviruses (Refer Wilson *et al*, *Virology* 353 (2006):294-306)
  - Designed compounds targeting E protein of SARS-1 and other human and animal coronaviruses
  - Since the COVID-19 outbreak Biotron has been screening its compounds for activity against SARS-CoV-2
    - Identified several that inhibit growth of SARS-CoV-2 (Refer BIT ASX announcement 7/9/20)
  - Currently expanding its SARS-CoV-2 screening, with aim of identifying compound(s) that may be progressed to the clinic



# HIV-1 Eradication

## Why is HIV-1 eradication necessary?

- Current antiretroviral drugs (ART) do not eradicate the virus
- Long-term health implications eg. HAND, immune activation, increase in malignancies and chronic diseases, drug-drug interactions
  - Major burden on healthcare systems

## Consequences in HIV

- Early onset CV disease
- Metabolic diseases
- Liver and kidney disease
- Cognitive impairment
- Increased frequency of cancer
- Frailty (incl. bone density)
- Excess healthcare burden / costs



# Significance of Results from BIT225 Phase 2 Trial

- **BIT225, a small molecule drug, combines direct-acting antiviral activity with immune modulatory effects**
- This is a unique mode of action; no other antiviral drug combines these two treatment paradigms
- BIT225 targets a key virus protein (Vpu) whose role is to mask infected cells from immune responses, leading to establishment of reservoirs
  - Trial data suggests that BIT225 effectively unmask HIV-infected cells so that they can be “seen” by the immune system which may lead to eradication
- Trial data also indicated that BIT225 reduced key measures of inflammation which has positive implication for health outcomes in this patient population

(Refer BIT ASX announcements 7/6/19, 11/7/19, 31/10/19, 3/12/19, 12/3/20, 22/6/20, 6/7/20 and 22/7/20)





# Outlook for 2020/2021 FY

- HIV-1 program is the prime focus
  - Conferring with KOLs/advisory group to map out late-stage clinical development
  - Progressing discussions with potential partners
- Continuing screening to identify lead anti-SARS-CoV-2 compound(s) to progress to next stage of development
- Hepatitis B (HBV) remains a promising early stage program. Additional resources are being committed to progress this to partner-ready status
- **Multiple partnering opportunities across Biotron's portfolio**



# Financial Information

## Key Financial Metrics

Ticker Code	ASX: BIT
Share Price (13/10/2020)	A \$0.105
Market Cap	A \$70 million
12 Month Trading Range	A \$0.05 – 0.185
Shares Outstanding	702 million
Cash Position (09/2020)	A \$7.66 million

## Board

Michael Hoy	Non-executive Chairman
Michelle Miller	Managing Director
Stephen Locarnini	Non-executive Director
Susan Pond	Non-executive Director
Robert Thomas	Non-executive Director



# BIOTRON LIMITED (ASX:BIT)

Michelle Miller  
Managing Director  
[mmiller@biotron.com.au](mailto:mmiller@biotron.com.au)  
[www.biotron.com.au](http://www.biotron.com.au)



*Biotron*